KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) FCF Margin (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of FCF Margin data on record, last reported at 28.73% in Q4 2025.

  • For Q4 2025, FCF Margin rose 4152.0% year-over-year to 28.73%; the TTM value through Dec 2025 reached 23.61%, up 1828.0%, while the annual FY2025 figure was 26.29%, 2096.0% up from the prior year.
  • FCF Margin reached 28.73% in Q4 2025 per EW's latest filing, down from 33.24% in the prior quarter.
  • Across five years, FCF Margin topped out at 49.76% in Q4 2022 and bottomed at 12.79% in Q4 2024.
  • Average FCF Margin over 5 years is 19.55%, with a median of 20.79% recorded in 2024.
  • Peak YoY movement for FCF Margin: crashed -4594bps in 2023, then surged 4152bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 28.1% in 2021, then surged by 77bps to 49.76% in 2022, then plummeted by -92bps to 3.81% in 2023, then plummeted by -435bps to 12.79% in 2024, then skyrocketed by 325bps to 28.73% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 28.73% in Q4 2025, 33.24% in Q3 2025, and 15.72% in Q2 2025.